Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.40 |
| ▸ | ACACA | Q13085 | 3/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 3/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.35 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30782864 | 1.00 | ACACB (0.40) | ACACBACACAPTGDRRAF1BRAF | |
| SCHEMBL30782901 | 0.87 | ACACB (0.41) | ACACBACACAPTGDRTHRBALDH1A1 | |
| SCHEMBL29982343 | 0.86 | ACACB (0.43) | ACACBACACAPTGDRTHRBALDH1A1 | |
| SCHEMBL20718106 | 0.86 | ACACB (0.43) | ACACBACACAPTGDRTHRBALDH1A1 | |
| SCHEMBL29980879 | 0.86 | ACACB (0.43) | ACACBACACAPTGDRTHRBALDH1A1 | |
| SCHEMBL29980816 | 0.86 | ACACB (0.43) | ACACBACACAPTGDRTHRBALDH1A1 | |
| SCHEMBL20718104 | 0.86 | ACACB (0.43) | ACACBACACAPTGDRTHRBALDH1A1 | |
| SCHEMBL20718103 | 0.86 | ACACB (0.43) | ACACBACACAPTGDRTHRBALDH1A1 | |
| SCHEMBL29981576 | 0.86 | ACACB (0.43) | ACACBACACAPTGDRTHRBALDH1A1 | |
| SCHEMBL29981623 | 0.84 | PTGDR (0.38) | ACACBACACAPTGDRTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250304546-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4593954-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI Drug Discovery LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250243173-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250129035-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2024073383-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129035-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | ACACB 673/4885ACACA 864/4885PTGDR 606/4885 |
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | ACACB 673/4885ACACA 864/4885PTGDR 606/4885 |
| US-20250304546-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | ACACB 673/4885ACACA 864/4885PTGDR 606/4885 |
| US-20250243173-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | ACACB 673/4885ACACA 864/4885PTGDR 606/4885 |
| US-20250388558-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | GRIN2C, SLC6A1, CLIC1 | ACACB 1097/4885ACACA 1193/4885PTGDR 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.